# OmiX Research and Diagnostics Laboratories Pvt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omix-research-and-diagnostics-laboratories-pvt

- Industry: Biotechnology
- Headquarters: Bangalore, India
- Website: www.omixdx.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Feb 26, 2019)
- Investors on record: 1

## About

OmiX Research and Diagnostics Laboratories Pvt Ltd specializes in providing innovative diagnostic solutions and research services in the health sector, focusing on enhancing disease detection and management through advanced technology.Founded in 2014 and headquartered in Bangalore, India, OmiX Research and Diagnostics Laboratories Pvt Ltd offers specialized diagnostic solutions. The firm has undergone strategic pivots to enhance its service offerings. Sudeshna Adak, the current CEO and founder, has a background in the healthcare industry. In February 2019, the company raised INR 17.49 million in Seed funding, led by Menterra Venture Advisors. The total amount raised by the firm is INR 17.49 million, with a current valuation of INR 109.509 million.OmiX Research and Diagnostics Laboratories Pvt Ltd provides a comprehensive range of diagnostic services and research support tailored to healthcare professionals and organizations. Their key offerings include advanced diagnostic assays, molecular testing, and integrated research solutions aimed at improving disease prevention and management. The company's services are designed for various segments within the healthcare market, including hospitals, clinics, and research institutions, focusing on delivering accurate and timely diagnostic information to aid in patient care and decision-making.In the most recent fiscal year of 2023, OmiX Research and Diagnostics Laboratories Pvt Ltd reported revenue of INR 52,614.30 and an EBITDA of INR 17,970.90.OmiX Research and Diagnostics Laboratories Pvt Ltd plans to leverage its recent funding from the Seed round in February 2019 to enhance its product offerings and expand into new markets. Upcoming products include advanced diagnostic tools aimed at specific disease areas, with launches expected in late 2024. The company is also targeting expansion into Southeast Asian markets by 2025, focusing on partnerships with local health organizations to increase its market presence and service capabilities.

## Funding rounds

- Seed, Feb 26, 2019, $0.3M — Menterra Venture Advisors

## Investors

- Menterra Venture Advisors (https://capitalatlas.ai/funds/menterra-venture-advisors) — Seed